Compare BioNTech SE - ADR (BNTX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vertiv Holdings Co — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Vertiv Holdings Co trades at $304.8 (market cap $116.61B). The key difference: Vertiv Holdings Co is far larger — about 5.1× BioNTech SE - ADR's market cap, and Vertiv Holdings Co pays a 0.08% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | VRT | |
|---|---|---|
Market Cap | $22.86B | $116.61B |
Sector | Health | Technology |
52-Week High | $119.34 | $376.23 |
52-Week Low | $83.89 | $121.82 |
Enterprise Value | $6.53B | $117.37B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Vertiv Holdings (VRT) trades at $305.87, down 4.07% today, amid strong fundamental performance with consistent earnings beats and robust AI-driven demand. The stock shows neutral technical signals with support at $300 and resistance at $314, while maintaining impressive profitability metrics including 45.1% ROE and 14.37% net margin. Recent news highlights Vertiv's $15 billion order backlog and expansion in Malaysia to capitalize on AI infrastructure growth.
The outlook remains positive with 94.7% analyst buy ratings and a $407.45 consensus target, representing 33% upside potential. Key risks include premium valuation multiples (P/E 76.28) and competitive pressures, but strong cash flow generation and AI infrastructure tailwinds support continued growth momentum through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
